

Remarks

Applicants provide herewith a Preliminary Amendment. This amendment cancels Claims 9, 10, 11, 15, 18 and 20 for the purposes of reducing costs and expediting prosecution only. Claims 16, 17 and 19 have been amended to remove multiple dependencies only.

Applicants have amended the specification (page 3, line 6 and page 3, line 22 of the published application) to introduce specific limitations to the values of L¹ and L² which find support in the specification as filed (see pages 10 and 12 and Claims 3 and 6, respectively).


Applicants have also amended the specification on or about page 91, line 16 (see published application) to correct the misnaming of the intermediate designated as (b) (2-{{[(2-Phenoxyethyl)thio]methyl}-5-{3-hydroxymethyl-4-[((2-piperidinoethyl)amino)carbonyl]phenyl}-1,3,4-oxadiazolo).

Applicants have amended Claim 13 to delete the last two compounds – one of which is a repeat and the other is a misnamed intermediate.

Applicants reserve the right to reintroduce, in this divisional application, any or all of the cancelled claims as appropriate.

Applicants believe no new matter has been added by operation of these amendments and respectfully request the amendments be entered into the record.

Respectfully submitted,



Francis O. Ginah
Attorney for Applicant(s)
Registration No. 44,712
Phone: 317-276-9477

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

April 12, 2006